Circulating miR-127-3p as a Potential Biomarker for Differential Diagnosis in Frontotemporal Dementia

J Alzheimers Dis. 2018;65(2):455-464. doi: 10.3233/JAD-180364.

Abstract

Given the heterogeneous nature of frontotemporal dementia (FTD), sensitive biomarkers are greatly needed for the accurate diagnosis of this neurodegenerative disorder. Circulating miRNAs have been reported as promising biomarkers for neurodegenerative disorders and processes affecting the central nervous system, especially in aging. The objective of the study was to evaluate if some circulating miRNAs linked with apoptosis (miR-29b-3p, miR-34a-5p, miR-16-5p, miR-17-5p, miR-107, miR-19b-3p, let-7b-5p, miR-26b-5p, and 127-3p) were able to distinguish between FTD patients and healthy controls. For this study, we enrolled 127 subjects, including 54 patients with FTD, 20 patients with Alzheimer's disease (AD), and 53 healthy controls. The qRT-PCR analysis showed a downregulation of miR-127-3p in FTD compared to controls, while the levels of other miRNAs remained unchanged. Then, miR-127-3p expression was also analyzed in AD patients, finding a different expression between two patient groups. A receiver operating characteristic curve was then created for miR-127-3p to discriminate FTD versus AD (AUC: 0.8986), and versus healthy controls (AUC: 0.8057). In conclusion, miR-127-3p could help to diagnose FTD and to distinguish it from AD.

Keywords: Biomarker; differential diagnosis; frontotemporal dementia; miR-127-3p; miRNA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Alzheimer Disease / blood
  • Biomarkers / blood
  • Circulating MicroRNA / blood*
  • Diagnosis, Differential
  • Female
  • Frontotemporal Dementia / blood*
  • Humans
  • Male
  • MicroRNAs / blood*
  • Sensitivity and Specificity

Substances

  • Biomarkers
  • Circulating MicroRNA
  • MIRN127 microRNA, human
  • MicroRNAs